Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer

被引:44
作者
Gaisa, Nadine T. [1 ]
Braunschweig, Till [1 ]
Reimer, Nina [1 ]
Bornemann, Joerg [2 ]
Eltze, Elke [3 ]
Siegert, Sabine [4 ]
Toma, Marieta [5 ]
Villa, Luigi [6 ]
Hartmann, Arndt [7 ]
Knuechel, Ruth [1 ]
机构
[1] Rhein Westfal TH Aachen, Inst Pathol, D-52074 Aachen, Germany
[2] Rhein Westfal TH Aachen, Electron Microscop Facil, D-52074 Aachen, Germany
[3] Inst Pathol Saarbruecken Rastpfuhl, Saarbrucken, Germany
[4] Inst Pathol LMU Munich, Munich, Germany
[5] Univ Dresden, Inst Pathol, Dresden, Germany
[6] Univ Hosp, Rhein Westfal TH Aachen, Div Nephrol, Aachen, Germany
[7] Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany
关键词
Squamous cell carcinoma; Bladder; CK; 5/6; 5/14; 20; Uroplakin; TRANSITIONAL-CELL CARCINOMAS; UROTHELIAL CARCINOMA; EPITHELIAL NEOPLASMS; CYTOKERATIN; 14; UROPLAKIN-III; EXPRESSION; MARKER; TUMORS; TRACT;
D O I
10.1007/s00428-010-1017-2
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Besides worse prognosis of bladder cancer with squamous differentiation (pure squamous cell carcinoma (SCC) or mixed urothelial carcinoma (UC/SCC)), high-grade non-keratinising squamous differentiation is difficult to identify in haematoxylin-eosin stainings. This study aims to validate routine immunohistochemical markers for squamous differentiation in a larger cohort of patients. Tissue microarrays of 89 pure SCCs and mixed UC/SCCs, 66 urothelial carcinomas (UC), precursor lesions and normal urothelium were stained for cytokeratin (CK) 5/6, CK 5/14, CK 7, CK 20 and uroplakin III. Electron microscopy was performed to confirm the differentiation. Pure SCCs displayed staining throughout the epithelium for CK 5/6 (76.6% (36/47)) and CK 5/14 (95.8% (46/48)), focal staining for CK 7 (28.9% (13/45)) and no staining for CK 20 and uroplakin III (both 0% (0/48)). UCs exhibited a basal or diffuse staining for CK 5/6 (30.2% (16/53)) and CK 5/14 (57.1% (32/56)), focal positivity for CK 7 (83.6% (46/ 55)), CK 20 (50.9% (29/57)) and uroplakin III (21.8% (12/55)). Each marker discriminated SCC and UC significantly (p < 0.01). A third subgroup rarely showed full epithelial staining for CK 5/6 (14.3% (1/7)) and CK 5/14 (28.6% (2/7)), focal staining for CK 7 (85.7% (6/7)) and no staining for CK 20 and uroplakin III (both 0% (0/7)). Electron microscopy could prove both, SCC and UC characteristics, revealing a transient type. A staining pattern with CK 5/6- and CK 5/14-positivity plus CK 20-and uroplakin III-negativity identified squamous differentiation in bladder tumours and revealed a third type of squamous transdifferentiation.
引用
收藏
页码:301 / 312
页数:12
相关论文
共 24 条
[1]   CYTOKERATIN POLYPEPTIDE PATTERNS OF DIFFERENT EPITHELIA OF THE HUMAN MALE UROGENITAL TRACT - IMMUNOFLUORESCENCE AND GEL-ELECTROPHORETIC STUDIES [J].
ACHTSTATTER, T ;
MOLL, R ;
MOORE, B ;
FRANKE, WW .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1985, 33 (05) :415-426
[2]  
[Anonymous], PATHOLOGY GENETICS T
[3]   Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases [J].
Chu, PG ;
Wu, E ;
Weiss, LM .
MODERN PATHOLOGY, 2000, 13 (09) :962-972
[4]   Expression of cytokeratin 5/6 in epithelial neoplasms: An immunohistochemical study of 509 cases [J].
Chu, PGG ;
Weiss, LM .
MODERN PATHOLOGY, 2002, 15 (01) :6-10
[5]   The effect of squamous and/or glandular differentiation on recurrence, progression and survival in urothelial carcinoma of bladder [J].
Erdemir, Fikret ;
Tunc, Murat ;
Ozcan, Faruk ;
Parlaktas, Bekir S. ;
Uluocak, Nihat ;
Kilicaslan, Isin ;
Gokce, Ozgur .
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2007, 39 (03) :803-807
[6]  
Ferlay J., 2004, IARC Cancer Base, V5
[7]   Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder [J].
Gee, JR ;
Montoya, RG ;
Khaled, HM ;
Sabichi, AL ;
Grossman, HB .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2003, 21 (04) :266-270
[8]   Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas [J].
Harnden, P ;
Southgate, J .
JOURNAL OF CLINICAL PATHOLOGY, 1997, 50 (12) :1032-1033
[9]   Expression of cytokeratin 20 redefines urothelial papillomas of the bladder [J].
Harnden, P ;
Mahmood, N ;
Southgate, J .
LANCET, 1999, 353 (9157) :974-977
[10]   Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas [J].
Kaufmann, O ;
Volmerig, J ;
Dietel, M .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (05) :683-687